undamentalytics Newsletter
Sign in

Colgate-Palmolive (CL) stock

Add to watchlist

Add holding +

NYSE: CL NYSE Household Products Next results ~January 29, 2027

B Fundamentals grade

Colgate-Palmolive is a consumer products company whose goods are marketed in over 200 countries and territories. Its Oral, Personal and Home Care segment makes toothpaste, toothbrushes and mouthwash under names including Colgate, Darlie, elmex, hello, meridol, Sorriso and Tom's of Maine, alongside pharmaceutical items for dental professionals. The same segment covers hand and bar soaps, shower gels and deodorants such as Palmolive, Protex, Softsoap, Irish Spring, Speed Stick and Sanex, skin health lines EltaMD, Filorga and PCA SKIN, and home care brands including Ajax, Fabuloso, Murphy and Suavitel.

The separate Hill's Pet Nutrition segment sells specialty foods for dogs and cats under Science Diet, Prescription Diet and the Australian fresh-food brand Prime100, available in over 80 countries and territories.

Revenue comes from selling these products to retailers, wholesalers and distributors, with pet foods sold through authorised pet supply retailers, veterinarians and eCommerce, plus some direct-to-consumer sales; marketing increasingly emphasises digital channels. Walmart accounted for around 11% of net sales in 2025, with no other customer above 10%. The company was founded in 1806 and incorporated in Delaware in 1923.

Based on Colgate-Palmolive's 10-K filed February 23, 2026.

Stock price today

Loading chart…

Third-party market data · may be delayed

Fair value per share

~$81

Cash-flow model

Base case. Range ~$59–$110 across our lower- and higher-growth cases (-0.2%–9.8% a year).

Price vs value

Modestly overvalued

The price is inside our value range, 20% above our base value.

Price used: $97.43, November 2, 2026

Colgate-Palmolive valuation: adjust assumptions and compare models →

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

Value diary

Our note on each quarter Colgate-Palmolive files

10-Q filed October 30: Colgate-Palmolive

Model value +4.0%

Colgate-Palmolive grew revenue to $21.3bn over the twelve months to September 2026, a 5.9% increase that accelerated from 5.2% growth the previous quarter. Among the nine household products companies we cover, that places the firm second for growth. Margins told a mixed story: free-cash-flow margin held steady at 17.8%, while operating margin narrowed sharply to 14.8% from 21.3%. Our model value has moved up from $78.03 to $81.19 a share, still well below the $95.29 share price, so the rating remains Hold. At the current price, the market appears to be pricing in cash-flow growth of about 6.9% a year over five years, well ahead of the 4.1% annual revenue growth the company has actually delivered.

Source: 10-Q filed October 30, 2026 on SEC EDGAR · Financials · Valuation

Earlier notes (2)

10-Q filed July 31: Colgate-Palmolive

Colgate-Palmolive generated $21.3bn in revenue over the twelve months to June 2026, a 5.9% rise on a year earlier and an acceleration from the 5.2% growth posted a quarter before. Among the nine household products companies we cover, that places it second for growth. Free-cash-flow margin was unchanged at 17.8%, while operating margin narrowed sharply to 14.8% from 21.3%. The fundamentals grade improves from C+ to B+. Our model value is barely changed at $78.03 a share, well below the $92.39 share price, so the rating remains Hold. At the current price, the market appears to be pricing in cash-flow growth of about 7.0% a year over five years, a faster pace than the 4.1% a year revenue growth the company has actually delivered.

10-Q on SEC EDGAR

Where Colgate-Palmolive stands after its latest 10-Q

Revenue for the twelve months to June 2026 was $21.0bn, up 5.2% on a year earlier, faster than 4.3% a quarter earlier. Free-cash-flow margin rose to 18.3% from 16.9% a year earlier. Operating margin narrowed to 14.9% from 21.4%. Against its peers on growth, profitability, cash generation and balance sheet, it grades C+. It passes 3 of our 7 financial-health checks. Our cash-flow model value is $76.17 a share, against a share price of $94.04. At that price, our model says the market is pricing in about 8.1% a year of cash-flow growth for five years, faster than the 3.9% a year revenue growth it has delivered.

10-Q on SEC EDGAR

Written from the company's filings and our models when each quarter's report arrives. Figures in older notes are as published at the time. Not investment advice.

The Fundamentalytics view

Next results ~January 29, 2027 (estimated)

Colgate-Palmolive's trailing-twelve-month revenue grew 5.9% year on year, with a free-cash-flow margin of 17.8%. Where it stands out: free-cash-flow margin of 17.8% ranks 1 of 12 household products companies we cover. Where it lags: long-term debt as % of assets of 42.9% ranks 9 of 10 household products companies we cover.

Our discounted-cash-flow model values the business at ~$81 per share in the base case (~$59–$110 across growth scenarios) — model values under stated assumptions, not a price target.

Current signal Free cash flow diverging from earnings: TTM free cash flow grew 10.0% while net income fell 29.4%: a 39pp divergence.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

  • Shrinking share count. Diluted shares fell 1.4% in a year, so each share owns more of the business.
  • Beating expectations. Earnings per share beat the analysts' consensus estimate in each of the last four quarters.

Things to watch

  • Margins narrowing. Operating margin is down 6.4 points on a year ago.
  • Insiders selling. 8 insiders sold $57M of stock over the past 365 days and none bought (0% under pre-set trading plans).
  • Below peers: long-term debt as % of assets. Long-term debt as % of assets of 42.9% ranks 9 of 10 household products companies we cover (median 31.5%).

Latest results: FY2026 Q3

Filed October 30, 2026
Earnings per share
$0.97 against an average estimate of $0.93: beat by 4.8%
Revenue
$5.37bn, up 4.6% on a year earlier
Share reaction
+4.6% in the first session after the results on October 30, 2026, against -2.2% for the S&P 500
Guidance given
net sales growth 4% to 5% (full year 2026); base Business earnings per share growth growth 5% to 7% (full year 2026)
Next report
January 29, 2027; average EPS estimate $0.96

Colgate-Palmolive's figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day+2.2%
  • 1 week+4.7%
  • 1 month+16.3%
  • This year+26.3%
  • 1 year+29.5%
  • 5 years+42.0%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Profitability

Revenue (TTM)
$21.3B
Operating margin
14.8%
Net margin
9.6%
EPS (TTM, diluted)
$2.56

Growth

Revenue growth
+5.9%
Change in growth rate
+0.7 pts
Share count change
−1.4%

Cash

Free cash flow (TTM)
$3.8B
FCF margin
17.8%
Stock pay % of revenue
0.8%

Earnings

Last results
October 30, 2026
Next results (est.)
January 29, 2027

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Results
  2. Guidance
  3. Insider trade
  4. Insider trade
  5. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Colgate-Palmolive valuation models and calculator

What the price is pricing in

The share price implies about 7.0% a year of cash-flow growth for five years.That is close to the 4.1% a year revenue growth Colgate-Palmolive has delivered.

  • Priced in7.0%
  • Last 12 months5.9%
  • 3 years a year3.6%
  • 5 years a year4.1%

Our cash-flow model with every input fixed except growth over the next five years, solved for the growth at which the model value equals the share price ($96.17, Nov 3, 2026). Cash-flow growth then fades to 2.5% a year; discount rate 8.5%. Delivered figures are revenue growth from SEC filings. This is a model exercise, not investment advice or a forecast of the share price. All companies

Fundamentalytics rating

model v1.6 · 2026-11-03
Hold12-month view
12-month price target
~$81
Price used
$96.17close November 3, 2026
Implied change
▼ 16%
Uncertainty
Medium

How we got here: a discounted-cash-flow model of Colgate-Palmolive's free cash flow after stock-based pay with after-tax interest added back ($3.7B, FY2026 Q3 TTM), growing 3.1% and 4.2% in the next two years (forecasts, guidance and its record), then back to 4.8% by year five, and fading to 2.5%, discounted at 8.5%. Lower and higher growth cases span ~$59–~$110 ; that spread sets a 25% margin before we rate Buy or Sell.

Produced by Fundamentalytics' automated valuation model on November 3, 2026, using delayed market prices. Rating meanings, methodology and conflicts: recommendations disclosure and research disclaimer. General research, not personal advice — it does not consider your circumstances. Prices can fall as well as rise.

Our value per share comes from a discounted-cash-flow model of Colgate-Palmolive's free cash flow after stock-based pay ( $3.7B, FY2026 Q3 TTM, with after-tax interest added back): growth for five years as below (the first two years from forecasts, guidance and the company's record), fading to 2.5%, discounted at 8.5%, then cash added and debt and other claims subtracted. These are model values under stated assumptions, not price targets or recommendations.

Valuation models

We value Colgate-Palmolive as an operating company, with every model that fits that kind of business. Cost of equity 7%: the 10-year Treasury yield (4.9%) plus a beta of 0.4 times a 4.5% equity risk premium.

Value per share by model
Model Value per share In the combined value?
Cash-flow model (DCF) Free cash flow to the firm (after stock pay, with after-tax interest added back), grown then faded to 2.5%, discounted at 8.5% as the firm rate, less debt and other claims. ~$81 ~$59–$110 Primary model, counts double
Forward price-to-earnings vs peers Next year's consensus earnings per share times peers' typical (harmonic-mean) forward price-to-earnings. Uses analysts' consensus estimates (third-party data), not our forecasts. ~$60 ~$60–$75 Included
Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. — Does not apply: return on equity above 40%: buybacks or intangibles make book value too small an anchor
Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. ~$70 ~$56–$94 Included
Combined value Weighted average of the models that apply: the primary model (cash-flow model (dcf)) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. ~$73 ~$60–$81 3 models

Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Colgate-Palmolive with Household Products in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.

What moves the value

  • Revenue growth 5 points lower ▼ −27%
  • Revenue growth 5 points higher ▲ +35%
  • Free-cash-flow margin 1 point lower ▼ −6%
  • Last year's free-cash-flow margin change, if it persists ▲ +4%
  • Discount rate 1 point higher ▼ −16%
Value per share under different assumptions
Discount rate ↓ / growth → −5% growth0% growth5% growth10% growth15% growth20% growth
7% $60$84$116$158$213$285
8.5% $44$62$85$115$154$205
10% $35$48$66$89$119$157

Valuation multiples over time Market data may be delayed

At fiscal year end 20152016201720182019202020212022202320242025Now
Share price$51.44$51.67$60.91$49.22$58.37$74.23$75.78$71.65$74.36$86.68$77.17$97.43
Market value$46.8bn$46.4bn$54.1bn$43.0bn$50.3bn$63.8bn$64.3bn$60.1bn$61.7bn$71.4bn$62.6bn$78.2bn
+ Net debt (− = net cash)$5.6bn$5.2bn$5.0bn$5.6bn$6.7bn$6.5bn$6.4bn$8.0bn$7.3bn$6.8bn$6.7bn$5.7bn
Enterprise value$52.4bn$51.6bn$59.1bn$48.6bn$57.0bn$70.2bn$70.7bn$68.1bn$68.9bn$78.2bn$69.3bn$83.9bn
Multiples
Price / sales 2.9x3.1x3.5x2.8x3.2x3.9x3.7x3.3x3.2x3.5x3.1x3.7x
Price / earnings 33.8x19.0x26.7x17.9x21.2x23.7x29.7x33.7x26.8x24.7x29.4x38.1x
Price / free cash flow 20.7x18.2x21.6x16.4x18.0x19.3x23.3x32.3x20.3x20.1x17.2x20.7x
EV / EBITDA 16.2x11.7x14.1x11.6x14.0x15.9x18.2x19.8x15.1x16.0x17.6x22.1x

Market value uses the period's diluted share count; figures for each fiscal year use that year's results and the price at year end. "Now" uses today's price and the last twelve months.

Moat

88 /100

Strong moat

How hard Colgate-Palmolive's competitive advantage looks for rivals to wear away, judged from 10 years of its own filings: returns on capital, pricing power, profit durability, cash conversion and discipline.

  • Returns on capital 20 / 20

    Cash operating profit has been a median 25.7% of total assets over 10 years.

  • Pricing power 20 / 20

    Gross margin has been a median 60.2%, moving by 1.1 percentage points (standard deviation) across 10 years.

  • Durability 16 / 20

    Operating margin has been a median 22.0%; its worst year was 14.8%.

  • Cash conversion 18 / 20

    Free cash flow was positive in 10 of 10 years, at a median 16.8% of revenue.

  • Discipline 19 / 20

    The diluted share count fell 5.7% over five years; stock-based pay has been a median 0.7% of revenue.

AI disruption exposure: Medium. In this industry, AI could change how the product is made or sold, without replacing the core asset. The score above includes a 5-point deduction for that exposure (93 before it).

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Next results: January 29, 2027, before the open. Analysts expect revenue of $5.4bn and EPS of $0.96 (range $0.93 to $0.99) for the quarter.

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current $3.87 +5% $21.4bn +5%
Next $4.09 +6% $22.1bn +3%

Next year's EPS estimate has moved +0.8% in 90 days, across 20 analysts.

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is +1.4% on 90 days ago. In the last 30 days, 0 analysts raised Colgate-Palmolive's forecast and 3 cut it.

Consensus EPS forecast Colgate-Palmolive, last 90 days
$3.80 $3.90 $4.00 $4.10 $4.20 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: $3.81 Current fiscal year, 60 days ago: $3.88 Current fiscal year, 30 days ago: $3.87 Current fiscal year, 7 days ago: $3.87 Current fiscal year, Now: $3.87 $3.87 Next fiscal year, 90 days ago: $4.05 Next fiscal year, 60 days ago: $4.11 Next fiscal year, 30 days ago: $4.10 Next fiscal year, 7 days ago: $4.09 Next fiscal year, Now: $4.09 $4.09

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago $3.81$4.05
60 days ago $3.88$4.11
30 days ago $3.87$4.10
7 days ago $3.87$4.09
Now $3.87$4.09

Earnings against estimates

Quarter toEstimateActualSurprise
Sept 2026 $0.93 $0.97 +4.8%
Jun 2026 $0.95 $0.99 +4.5%
Mar 2026 $0.94 $0.97 +2.7%
Dec 2025 $0.91 $0.95 +4.2%

Adjusted EPS as companies report it, against the average analyst estimate.

Management guidance

Earnings release, October 30, 2026
  • net sales full year 2026 4% growth to 5% growth Narrowed
    “The Company now expects net sales to be up 4% to 5% (versus 2% to 6% previously), including a low-single-digit positive impact from foreign exchange.” source
  • Base Business earnings per share growth full year 2026 5% growth to 7% growth Non-GAAP Raised
    “it also now expects 5% to 7% earnings per share growth (versus mid-single-digit growth previously).” source

Figures and quotations are management's, copied from the company's own press release (SEC 8-K exhibit) and checked word for word against it. Forward-looking statements are the company's expectations, not ours and not advice; guidance can change or be missed.

How our valuation uses these forecasts

Our cash-flow model grows Colgate-Palmolive's revenue by +3.1% next year and +4.2% the year after, then fades back toward its own record by year five. Next year's rate weighs analysts' consensus (+2.9%, weight 48%) , management guidance (+2.4%, weight 31%) and the company's own record (+4.8%, weight 21%) . How the weights are set.

Analyst recommendations

21 analysts, Oct 2026
Buy1362%
Hold733%
Sell15%

Monthly trend

  1. Oct 202667721
  2. Sep 202667821
  3. Aug 202667821
  4. Jul 202667821

Counts of recommendations published by analysts covering Colgate-Palmolive, by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
2.5%
of tradable shares
Days to cover
3.19
at average volume
Short interest, 1 month
−5%
to October 15, 2026
Held by institutions
87%
of shares
Held by insiders
0.1%
of shares
Employees
33,600
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

What moved the share price

Last 12 months +29.5%

$75.24 on October 31, 2025 to $97.43

ThenNowEffect
Revenue (last 12 months) $20.0bn $21.0bn +5.2%
Net margin 14.5% 9.7% −33.5%
P/E multiple 21.2x 38.5x +82.2%
Share count 818m 806m +1.5%

Biggest factor: p/e multiple.

Last 3 years +39.6%

$69.80 on November 3, 2023 to $97.43

ThenNowEffect
Revenue (last 12 months) $18.7bn $21.0bn +12.7%
Net margin 8.0% 9.7% +20.7%
P/E multiple 38.9x 38.5x −0.9%
Share count 834m 806m +3.5%

Biggest factor: net margin.

The effects multiply back to the price change exactly. Results are the last 12 months as known on each date (filings assumed public 45 days after quarter end).

Return and risk by year

Calendar year 202120222023202420252026 to date
Return
CL+2%−5%+4%+17%−11%+26%
Industry peers (median)+9%−20%+5%+8%−20%+15%
S&P 500+29%−18%+26%+25%+18%+11%
Months that ended higher
CL42%50%50%75%42%73%
S&P 50075%42%67%75%75%46%
Largest fall from a high during the year
CL−13%−18%−16%−17%−22%−17%
S&P 500−5%−25%−10%−8%−19%−9%

Worst fall since November 2, 2015: 29% from September 4, 2024 to November 3, 2025. Getting back needed a 41% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$73.22 – $97.43
From 52-week high
0.0%
vs 50-day average
+9.1%
vs 200-day average
+9.8%
Volatility (1 year)
23%
Beta vs S&P 500
-0.17

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±2.8%
After a week
9 up, 2 down
typical move ±3.9%
After a month
9 up, 2 down
typical move ±4.2%
Results releasedNext dayS&P 500 next day5 days21 days
October 30, 2026 +4.6% −2.2% — —
July 31, 2026 −1.9% +2.2% +1.8% −1.9%
May 1, 2026 0.0% −0.1% +2.6% +3.4%
January 30, 2026 +7.8% +0.2% +10.8% +12.0%
October 31, 2025 −2.0% +0.5% +2.9% +3.0%
August 1, 2025 −0.6% −0.1% +1.0% +0.6%
April 25, 2025 −1.9% +0.8% −2.4% −0.3%
January 31, 2025 −4.2% −1.2% −4.5% +0.2%
July 26, 2024 +4.5% +1.2% +6.5% +8.9%
April 26, 2024 +1.3% +1.3% +4.0% +3.0%
January 26, 2024 +3.4% +0.7% +4.2% +6.4%
October 27, 2023 +1.1% +0.7% +2.4% +6.6%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Options strategies

All options ideas

How Colgate-Palmolive’s listed options are priced, and three ways to use them that follow from our valuation. Quotes are delayed, read November 2, 2026. Check the live chain at your broker before trading.

Implied vs realised volatility

Results just out

Results came out in the last few days. Option prices are still adjusting, so we do not judge them yet.

  • Implied is 1.27× the last 60 days’ realised volatility .
  • Why: results came out in the last few days, so option prices are still adjusting.

Our rule for “rich”: implied at least 1.2× 60-day realised (beyond measurement noise), above 1-year realised (not just a calm spell), and in the top 20% of our coverage that day. Never with results inside the option’s life. These are our conventions, built on research showing option prices usually imply more movement than follows, most when the gap is wide. How we judge this.

Cash-secured put

Not offered: fundamentals grade B (needs B+ or better).

We suggest selling a put only on well-rated companies, at a strike where the price you would pay if assigned (strike less premium) is at or below our fair value.

CL Colgate-Palmolive Grade B $97.29

Own 100 shares, sell the $99.00 call expiring November 27, 2026 (25 days) for $1.75 a share — $175 per contract.

Previous session · Bid $1.75, ask $2.15, quoted Mon 2 Nov, 17:18 New York time with CL at $97.29. Option prices move with the shares: check the live chain at your broker before trading.

  • If CL ends below $99.00: you keep your shares and the $175 — 1.8% extra on the position, 26.3% a year at that pace.
  • If it ends above $99.00: your shares are sold at $99.00, a total return of 3.6% including the premium — at or above our value of ~$81.
$346 $0 −$1.9k Our value $81.00 Break-even $95.54 Price $97.29
Profit or loss per contract at expiry, by share price (including the shares bought at today's price).
Premium
$175
Annualised
26.3%
Break-even
$95.54
Max gain
$346
Chance of selling
~43%

Collar

Own the shares, buy the $92.50 put and sell the $100 call, both expiring December 18, 2026 (46 days).

  • Net credit of $0.90 a share ($90.00 per contract of 100 shares).
  • Worst case at expiry: -4.0%, if the shares fall below $92.50 (-4.9% from today).
  • Best case at expiry: +3.7%, if the shares rise above $100 (+2.8%); gains beyond that go to the call buyer.

Offered because the shares trade at or above our fair value of $81.00: a way to hold on with a floor under the price, paid for by giving up upside the model does not expect. Strikes near 25-delta; the put at its ask and the call at its bid. Protection has a cost over time: research on protective puts finds they have usually lowered returns.

General research, not personal advice. Options can lose you more than you expect and are not suitable for everyone: put sellers can be made to buy shares that keep falling, call sellers give up gains above the strike, and results or news can move prices sharply. Chances shown are approximations from each option’s delta. Spreads, fees and early assignment are not modelled.

Colgate-Palmolive in five measures

Fundamentals grade B
Growth Profitability Cash Balance sheet Value

Growth, profitability, cash generation and balance sheet are percentiles against the companies we cover in the same industry, from SEC filings (100 = best). Value compares the share price with our modelled value range (50 = at our base value; higher = cheaper). A description of reported data and our model — not a quality score or advice.

Fundamentals

Revenue (TTM) Colgate-Palmolive
$19B $19.5B $20B $20.5B $21B $21.5B FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue (TTM), FY23 Q4: $19.5B Revenue (TTM), FY24 Q1: $19.8B Revenue (TTM), FY24 Q2: $20B Revenue (TTM), FY24 Q3: $20.1B Revenue (TTM), FY24 Q4: $20.1B Revenue (TTM), FY25 Q1: $19.9B Revenue (TTM), FY25 Q2: $20B Revenue (TTM), FY25 Q3: $20.1B Revenue (TTM), FY25 Q4: $20.4B Revenue (TTM), FY26 Q1: $20.8B Revenue (TTM), FY26 Q2: $21B Revenue (TTM), FY26 Q3: $21.3B $21.3B

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Revenue (TTM)
FY23 Q4 $19.5B
FY24 Q1 $19.8B
FY24 Q2 $20B
FY24 Q3 $20.1B
FY24 Q4 $20.1B
FY25 Q1 $19.9B
FY25 Q2 $20B
FY25 Q3 $20.1B
FY25 Q4 $20.4B
FY26 Q1 $20.8B
FY26 Q2 $21B
FY26 Q3 $21.3B
Revenue growth, TTM YoY Colgate-Palmolive
-5% 0% 5% 10% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Revenue growth, TTM YoY, FY23 Q4: 8.3% Revenue growth, TTM YoY, FY24 Q1: 7.7% Revenue growth, TTM YoY, FY24 Q2: 7.0% Revenue growth, TTM YoY, FY24 Q3: 5.1% Revenue growth, TTM YoY, FY24 Q4: 3.3% Revenue growth, TTM YoY, FY25 Q1: 1.0% Revenue growth, TTM YoY, FY25 Q2: 0.1% Revenue growth, TTM YoY, FY25 Q3: -0.0% Revenue growth, TTM YoY, FY25 Q4: 1.4% Revenue growth, TTM YoY, FY26 Q1: 4.3% Revenue growth, TTM YoY, FY26 Q2: 5.2% Revenue growth, TTM YoY, FY26 Q3: 5.9% 5.9%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Revenue growth, TTM YoY
FY23 Q4 8.3%
FY24 Q1 7.7%
FY24 Q2 7.0%
FY24 Q3 5.1%
FY24 Q4 3.3%
FY25 Q1 1.0%
FY25 Q2 0.1%
FY25 Q3 -0.0%
FY25 Q4 1.4%
FY26 Q1 4.3%
FY26 Q2 5.2%
FY26 Q3 5.9%
Operating margin (TTM) Colgate-Palmolive
14% 16% 18% 20% 22% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 Operating margin (TTM), FY23 Q4: 20.5% Operating margin (TTM), FY24 Q1: 20.9% Operating margin (TTM), FY24 Q2: 21.2% Operating margin (TTM), FY24 Q3: 21.3% Operating margin (TTM), FY24 Q4: 21.2% Operating margin (TTM), FY25 Q1: 21.5% Operating margin (TTM), FY25 Q2: 21.4% Operating margin (TTM), FY25 Q3: 21.3% Operating margin (TTM), FY25 Q4: 16.2% Operating margin (TTM), FY26 Q1: 15.4% Operating margin (TTM), FY26 Q2: 14.9% Operating margin (TTM), FY26 Q3: 14.8% 14.8%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period Operating margin (TTM)
FY23 Q4 20.5%
FY24 Q1 20.9%
FY24 Q2 21.2%
FY24 Q3 21.3%
FY24 Q4 21.2%
FY25 Q1 21.5%
FY25 Q2 21.4%
FY25 Q3 21.3%
FY25 Q4 16.2%
FY26 Q1 15.4%
FY26 Q2 14.9%
FY26 Q3 14.8%
FCF margin (TTM) Colgate-Palmolive
15% 16% 17% 18% 19% FY23 Q4 FY24 Q3 FY25 Q2 FY26 Q3 FCF margin (TTM), FY23 Q4: 15.6% FCF margin (TTM), FY24 Q1: 15.3% FCF margin (TTM), FY24 Q2: 16.8% FCF margin (TTM), FY24 Q3: 16.9% FCF margin (TTM), FY24 Q4: 17.6% FCF margin (TTM), FY25 Q1: 17.4% FCF margin (TTM), FY25 Q2: 16.9% FCF margin (TTM), FY25 Q3: 17.1% FCF margin (TTM), FY25 Q4: 17.8% FCF margin (TTM), FY26 Q1: 18.1% FCF margin (TTM), FY26 Q2: 18.3% FCF margin (TTM), FY26 Q3: 17.8% 17.8%

Source: SEC EDGAR filings. Retrieved November 3, 2026.

View chart data
Period FCF margin (TTM)
FY23 Q4 15.6%
FY24 Q1 15.3%
FY24 Q2 16.8%
FY24 Q3 16.9%
FY24 Q4 17.6%
FY25 Q1 17.4%
FY25 Q2 16.9%
FY25 Q3 17.1%
FY25 Q4 17.8%
FY26 Q1 18.1%
FY26 Q2 18.3%
FY26 Q3 17.8%

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms 10-K, 10-K/A, 10-Q. Generated November 3, 2026. Definitions in our methodology.

Where the money goes

FY2025, from the 10-K

Each dollar Colgate-Palmolive took in during FY2025, followed through to profit: what it cost to make, what went on research and running the business, and what was left after tax.

  1. Revenue $20.4B
  2. Cost of revenue $8.1B · 39.9%
  3. Gross profit $12.3B · 60.1%
  4. Research and development $366M · 1.8%
  5. Selling, general and admin $7.9B · 38.8%
  6. Other operating costs $676M · 3.3%
  7. Operating income $3.3B · 16.2%
  8. Income tax $798M · 3.9%
  9. Interest and other $376M · 1.8%
  10. Net income $2.1B · 10.5%

Shares of revenue. Source: Colgate-Palmolive's 10-K for FY2025, as filed with the SEC. "Other" lines are what the reported lines leave unexplained.

Financial statements

US$ billions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year 2009 Dec 2009 2010 Dec 2010 2011 Dec 2011 2012 Dec 2012 2013 Dec 2013 2014 Dec 2014 2015 Dec 2015 2016 Dec 2016 2017 Dec 2017 2018 Dec 2018 2019 Dec 2019 2020 Dec 2020 2021 Dec 2021 2022 Dec 2022 2023 Dec 2023 2024 Dec 2024 2025 Dec 2025 LTM Sept 2026
Income
Revenue 15.3 15.6 16.7 17.1 17.4 17.3 16.0 15.2 15.5 15.5 15.7 16.5 17.4 18.0 19.5 20.1 20.4 21.3
Gross profit 9.0 9.2 9.6 9.9 10.2 10.1 9.4 9.1 9.3 9.2 9.3 10.0 10.4 10.2 11.3 12.2 12.3 12.9
EBITDA 4.0 3.9 4.3 4.3 4.0 4.0 3.2 4.4 4.2 4.2 4.1 4.4 3.9 3.4 4.6 4.9 3.9 3.8
Operating income 3.6 3.5 3.8 3.9 3.6 3.6 2.8 4.0 3.7 3.7 3.6 3.9 3.3 2.9 4.0 4.3 3.3 3.2
Net income 2.3 2.2 2.4 2.5 2.2 2.2 1.4 2.4 2.0 2.4 2.4 2.7 2.2 1.8 2.3 2.9 2.1 2.1
Diluted EPS $2.19 $2.15 $2.47 $2.57 $2.38 $2.36 $1.52 $2.72 $2.28 $2.75 $2.75 $3.14 $2.55 $2.13 $2.77 $3.51 $2.63 $2.56
Growth (year on year)
Revenue −0.0% +1.5% +7.5% +2.1% +2.0% −0.8% −7.2% −5.2% +1.7% +0.6% +1.0% +5.0% +5.8% +3.1% +8.3% +3.3% +1.4% +5.9%
EBITDA +15.0% −2.5% +10.3% +1.2% −7.4% +0.1% −19.0% +35.8% −4.9% +0.6% −3.1% +8.6% −12.1% −11.6% +32.4% +7.1% −19.2% −22.1%
Operating income +16.6% −3.5% +10.1% +1.2% −8.6% +0.0% −21.6% +41.8% −6.3% −0.4% −3.8% +9.3% −14.2% −13.2% +37.7% +7.1% −22.5% −26.1%
Net income +17.1% −3.8% +10.3% +1.7% −9.3% −2.7% −36.5% +76.4% −17.1% +18.6% −1.4% +13.9% −19.6% −17.6% +28.9% +25.6% −26.2% −29.4%
Diluted EPS +19.4% −1.4% +14.6% +4.0% −7.4% −0.8% −35.6% +78.9% −16.2% +20.6% 0.0% +14.2% −18.8% −16.5% +30.0% +26.7% −25.1% −28.4%
Margins
Gross margin 58.8% 59.1% 57.3% 58.1% 58.6% 58.5% 58.6% 60.0% 60.0% 59.4% 59.4% 60.8% 59.6% 57.0% 58.2% 60.5% 60.1% 60.6%
EBITDA margin 25.9% 24.8% 25.5% 25.3% 22.9% 23.1% 20.2% 28.9% 27.1% 27.1% 26.0% 26.9% 22.3% 19.1% 23.4% 24.2% 19.3% 17.9%
Operating margin 23.6% 22.4% 23.0% 22.8% 20.4% 20.6% 17.4% 26.0% 24.0% 23.8% 22.6% 23.6% 19.1% 16.1% 20.5% 21.2% 16.2% 14.8%
Net margin 14.9% 14.2% 14.5% 14.5% 12.9% 12.6% 8.6% 16.1% 13.1% 15.4% 15.1% 16.4% 12.4% 9.9% 11.8% 14.4% 10.5% 9.6%
Free-cash-flow margin 17.6% 17.1% 14.1% 15.4% 14.5% 14.7% 14.1% 16.8% 16.2% 16.9% 17.8% 20.1% 15.8% 10.4% 15.6% 17.6% 17.8% 17.8%
Cash flow
Cash from operations 3.3 3.2 2.9 3.2 3.2 3.3 2.9 3.1 3.1 3.1 3.1 3.7 3.3 2.6 3.7 4.1 4.2 4.4
Capital spending 0.6 0.6 0.5 0.6 0.7 0.8 0.7 0.6 0.6 0.4 0.3 0.4 0.6 0.7 0.7 0.6 0.6 0.6
Free cash flow 2.7 2.7 2.4 2.6 2.5 2.5 2.3 2.5 2.5 2.6 2.8 3.3 2.8 1.9 3.0 3.5 3.6 3.8
Stock-based pay 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.1 0.2 0.2
Free cash flow after stock pay 2.6 2.5 2.2 2.5 2.4 2.4 2.1 2.4 2.4 2.5 2.7 3.2 2.6 1.7 2.9 3.4 3.5 3.6
Balance sheet
Cash 0.6 0.5 0.9 0.9 1.0 1.1 1.0 1.3 1.5 0.7 0.9 0.9 0.8 0.8 1.0 1.1 1.3 1.5
Total debt 3.1 3.4 4.8 5.2 5.6 6.1 6.5 6.5 6.6 6.4 7.6 7.3 7.2 8.8 8.2 7.9 8.0 7.2
Net debt (negative = net cash) 2.5 2.9 3.9 4.3 4.7 5.0 5.6 5.2 5.0 5.6 6.7 6.5 6.4 8.0 7.3 6.8 6.7 5.7
Diluted shares 1,049m 1,022m 984m 960m 940m 924m 910m 898m 888m 873m 861m 859m 848m 839m 829m 823m 811m 803m
Returned to shareholders
Dividends 1.0 1.1 1.2 1.3 1.4 1.4 1.5 1.5 1.5 1.6 1.6 1.7 1.7 1.7 1.7 1.8 1.8 1.8
Buybacks 1.1 2.0 1.8 1.9 1.5 1.5 1.6 1.3 1.4 1.2 1.2 1.5 1.3 1.3 1.1 1.7 1.2 1.3
Total returned 2.0 3.2 3.0 3.2 2.9 3.0 3.0 2.8 2.9 2.8 2.8 3.1 3.0 3.0 2.9 3.5 3.0 3.2

Source: SEC EDGAR XBRL company facts (US and foreign periodic filings); column headings link to the filing. EBITDA is operating income plus depreciation and amortisation. Free cash flow is cash from operations minus capital spending. Growth is left blank when last year's figure was a loss or under 2% of revenue. Share counts and EPS are restated for stock splits. A dash means the company didn't report the figure.

Financial health

2 of 7 checks passed · September 30, 2026
What it owns · $16.7bn
Short-term assets $6.4bnLonger-term assets $10.4bn
What it owes, and who funded it · $16.4bn
Short-term liabilities $6.6bnLonger-term liabilities $9.5bnShareholders' equity $288m
  • Short-term assets cover short-term liabilities $6.4bn of assets due within a year against $6.6bn of liabilities due within a year.
  • Short-term assets cover long-term liabilities $6.4bn short-term assets against $9.5bn of longer-dated liabilities.
  • More cash than debt $1.5bn of cash against $7.2bn of debt.
  • Debt below 40% of shareholders' equity Debt is 2494% of equity.
  • Debt burden no higher than five years ago Debt to equity moved from 2364% to 2494% over five years.
  • A year's operating cash flow covers at least 20% of debt $4.4bn of operating cash flow against $7.2bn of debt.
  • Operating profit covers interest at least five times over Operating income of $3.2bn against $250m of interest.

From Colgate-Palmolive's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Dividends, buybacks and capital spending

FY2026 Q3 TTM
Buybacks (TTM)
$1.3B
Dividends (TTM)
$1.8B
Returned to shareholders
84%
of free cash flow
Buybacks, last 3 fiscal years
$4.1B
Diluted share count
−1.4%
year over year
Total shareholder yield
4.1%
dividends 2.4% + buybacks 1.7% of market value
Dividend payout ratio
89%
of net income paid out
Sales & admin spending
39.4%
of revenue
Days sales outstanding
33 days
receivables vs revenue

Competitors: side by side with peers

Closest by revenue in household products
Last 12 months unless stated CL KMB UL CHD REYN CENT Median
Revenue, last 12 months $21.3bn $16.6bn $57.1bn $6.2bn $3.8bn $3.1bn $3.0bn
Revenue growth, last 12 months 5.9% 0.7% 0.6% 1.7% 2.7% −1.2% 1.9%
Revenue growth, 3-year average 3.6% −6.6% — 2.6% −0.7% −1.9% −0.6%
Revenue growth, latest quarter 4.6% 0.6% — 1.0% 0.6% −8.2% 1.0%
Gross margin 60.6% 36.8% 46.9% 46.1% 25.1% 32.5% 42.9%
Operating margin 14.8% 15.2% 17.9% 18.0% — 8.1% 11.5%
Operating margin, 3-year average 19.1% 15.7% 17.1% 16.0% — 7.4% 15.9%
Net margin 9.6% 11.8% 18.7% 12.4% 9.1% 5.4% 7.2%
Cash from operations / revenue 20.5% 20.1% 16.5% 19.3% 13.3% 12.7% 13.0%
Free-cash-flow margin 17.8% 11.0% 13.4% 16.9% 8.5% 11.2% 10.6%
Free-cash-flow margin, 3-year average 17.3% 14.1% 12.5% 16.0% 10.2% 10.1% 11.4%
Stock pay / revenue 0.8% 0.8% 0.5% 1.2% 0.5% 0.5% 0.8%
Change in share count −1.4% −0.4% −1.5% −3.3% 0.3% −4.5% −1.5%

Median of all 12 companies we cover in household products. Shaded: best of the six on that line (lowest for stock pay and share-count growth). 3-year figures average the last three 12-month periods; 3-year growth is compound annual. Source: SEC filings.

Peer comparison

12 household products companies
Measure Company Peer median Rank
Revenue growth Growth 5.9% 2.2% 4 of 12
Change in growth rate Growth +0.7pp -0.1pp 4 of 12
Gross margin Profitability 60.6% 46.1% 2 of 12
Operating margin Profitability 14.8% 14.8% 5 of 10
Net margin Profitability 9.6% 9.1% 5 of 12
Free-cash-flow margin Cash generation 17.8% 11.0% 1 of 12
Stock pay as % of revenue Cash generation 0.8% 0.8% 6 of 11
Long-term debt as % of assets Balance sheet 42.9% 31.5% 9 of 10
Change in share count Balance sheet -1.4% -1.4% 7 of 12
Days sales outstanding Balance sheet 33 days 45 days 2 of 11

Rank 1 = best in the group (for spending, debt and dilution, lower ranks first).

Where the revenue comes from

Fiscal year to December 31, 2025
Segments
Line of business Revenue Share YoY
Oral Personal and Home Care $15.8B 77.4% ▲ 1.0%
Pet Nutrition $4.6B 22.6% ▲ 2.9%

From Colgate-Palmolive's 10-K filed February 23, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Who owns it

Funds buying and selling
Reported value
$62.4B
Institutions reporting
2,012
Shares held vs prior quarter
▲ 1.1%
Positions opened / closed
161 / 101

Top buyers and sellers, Q2 2026: 888 institutions bought and 825 sold ; the biggest buyer was First Eagle Investment Management, LLC (+8.3M shares) and the biggest seller Price T Rowe Associates Inc (−5.8M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
Blackrock, Inc. $6.4B 69.9M 10.3% ▼ 3.8%
Vanguard Capital Management LLC $4.8B 52.2M 7.7% ▲ 0.1%
State Street Corp $4.3B 47.0M 6.9% ▼ 1.5%
Price T Rowe Associates Inc $2.6B 27.9M 4.1% ▼ 17.3%
Vanguard Portfolio Management LLC $2.2B 24.0M 3.5% ▲ 0.8%
Geode Capital Management, LLC $2.1B 23.1M 3.4% ▲ 1.1%
Morgan Stanley $2B 22.1M 3.2% ▲ 5.7%
First Eagle Investment Management, LLC $1.5B 16.4M 2.4% ▲ 102.2%
Bank Of New York Mellon Corp $1.2B 13.5M 2.0% ▲ 8.1%
Deutsche Bank Ag\ $1.1B 11.8M 1.7% ▼ 1.5%
Norges Bank $888M 9.7M 1.4% —
Acadian Asset Management LLC $834M 9.1M 1.3% ▲ 14.6%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Colgate-Palmolive's complete shareholder register. Values are as reported by the filers ; 3 inconsistently scaled filing rows were excluded.

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $57.1M 15 trades by 8 insiders · 0% under pre-set plans
Net ▼ $57.1M net selling
Insider Date Trade Shares Price Value
Tsourapas Panagiotis COO, CD, EMEA, APac, Skin August 24, 2026 Sell 10,000 $92.05 $920,477
Cahill John T Director August 6, 2026 Sell 4,170 $93.37 $389,358
Wallace Noel R. Chairman, President & CEO August 5, 2026 Sell 161,021 $92.52 $14.9M
Wallace Noel R. Chairman, President & CEO August 4, 2026 Sell 161,021 $91.92 $14.8M
Malcolm Gregory EVP and Controller May 15, 2026 Sell 2,300 $88.44 $203,412
Massey Sally Chief People Officer May 7, 2026 Sell 8,599 $87.41 $751,633
Tsourapas Panagiotis COO, Eur., APac, Afr Eur, Skin February 12, 2026 Sell 15,000 $97.81 $1.5M
Tsourapas Panagiotis COO, Eur., APac, Afr Eur, Skin February 11, 2026 Sell 35,000 $94.61 $3.3M
Hazlin John Chief Growth Officer February 10, 2026 Sell 20,989 $94.25 $2M
Malcolm Gregory EVP and Controller February 6, 2026 Sell 12,747 $94.91 $1.2M
Massey Sally Chief Human Resources Officer February 5, 2026 Sell 15,851 $95.03 $1.5M
Wallace Noel R. Chairman, President & CEO February 4, 2026 Sell 45,568 $93.91 $4.3M

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Trades by members of Congress

All 94 trades and filings

In the last 12 months, 1 member of Congress disclosed 0 purchases and 4 sales of Colgate-Palmolive shares.

  • Kevin Hern(R-OK 1):Sale (partial), $1,001 - $15,000, traded September 2, 2026, filed September 25, 2026
  • Kevin Hern(R-OK 1):Sale (full), $1,001 - $15,000, traded August 31, 2026, filed September 25, 2026
  • Kevin Hern(R-OK 1):Sale (partial), $1,001 - $15,000, traded August 27, 2026, filed September 25, 2026

Value ranges as filed; reports can arrive up to 45 days after a trade.

Earnings dates and SEC filings

Results announcements

Next expected around January 29, 2027 estimated from the company's past filing pattern, not announced

  • October 30, 2026
  • July 31, 2026
  • May 1, 2026
  • January 30, 2026
  • October 31, 2025
  • August 1, 2025

Recent SEC filings

Data status

When each part of this page on Colgate-Palmolive was last updated.

DataLast updatedSource
Share priceExchange closing prices
Financial statementsSEC 10-K and 10-Q filings
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Colgate-Palmolive in brief

What does Colgate-Palmolive do?
Colgate-Palmolive is a US-listed company in the household products industry. Its financial year ends in December.
What is Colgate-Palmolive's stock ticker?
Colgate-Palmolive trades under the ticker CL on NYSE. This page brings together its financial statements, valuation models, ownership and recent company updates.
What is Colgate-Palmolive's revenue, and how fast is it growing?
Over its most recent trailing twelve months, Colgate-Palmolive reported revenue of $21.3B, 5.9% higher than a year earlier, according to its SEC filings.
What is Colgate-Palmolive's free cash flow?
Colgate-Palmolive's free-cash-flow margin is 17.8% of revenue over the trailing twelve months, ranking 1 of the 12 household products companies we cover.
What is Colgate-Palmolive's fair value (intrinsic value) per share?
Our discounted-cash-flow model of Colgate-Palmolive's free cash flow after stock-based pay gives ~$81 per share in the base case, and ~$59–$110 across growth scenarios. These are model values under stated assumptions — not a price target or a recommendation.
Who are Colgate-Palmolive's largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are Blackrock, Inc., Vanguard Capital Management LLC and State Street Corp. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Is Colgate-Palmolive buying back stock, and does it pay a dividend?
Colgate-Palmolive spent $1.3B on share repurchases over the trailing twelve months, and its diluted share count fell 1.4% over the year.
What is Colgate-Palmolive's market cap?
On November 2, 2026, Colgate-Palmolive's market capitalisation was about $78.2B, with a price-to-earnings ratio of 38.1 and net debt of $5.7B. Market figures come from third-party market data and may be delayed.
Does Colgate-Palmolive pay a dividend?
Yes: Colgate-Palmolive paid $1.8B in dividends over the trailing twelve months, a dividend yield of 2.35% and a payout ratio of 89.2%.
How much debt does Colgate-Palmolive have?
Colgate-Palmolive's debt-to-equity ratio is 2494.4%, from its latest balance sheet (2363.9% five years earlier). The financial health section below sets out its other solvency checks.
Who are Colgate-Palmolive's competitors?
In our Household Products peer group, the companies closest to Colgate-Palmolive are Kimberly-Clark, Unilever PLC, Church & Dwight, Reynolds Consumer Products Inc. and Central Garden & PET Co. The side-by-side comparison below sets their revenue, margins and growth against Colgate-Palmolive's.
Are insiders buying or selling Colgate-Palmolive stock?
Over the last 12 months, Colgate-Palmolive's directors and officers reported 0 open-market purchases and 15 sales on Form 4. The insider trading page charts every trade.
When is Colgate-Palmolive's next earnings date?
Around January 29, 2027, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Colgate-Palmolive announces its own schedule.